top of page

Pulsipher et al. PLoS One 2021

Therapeutic Strategy

Most therapeutic strategies for oncology target key molecules involved in the late stages of disease progression and are not mechanistically based on the recent understanding of disease. As an innovative mechanism-based solution, GlycoMira’s proprietary lead asset — GM-1111 — potently inhibits innate immune receptor activation at the earliest stage of disease to mitigate further progression and ultimately result in improvements in treatment efficacy and patient outcomes.

Technology Banner

Technology

GM-1111 Enhances Tumor  Radiation Therapy

Preclinical data demonstrate that GM-1111 enhances the efficacy of radiation therapy.  In the graph below, from a mouse model of human head and neck cancer, GM-1111 administration in conjunction with radiation produced a highly significant reduction in tumor volumes compared to radiation treatment alone.

GM1111  Enhances Tumor Suppression Effects of Radiotherapy

GM-1111 Mitigates Oral Mucositis

In an animal model of radiation-induced oral mucositis treatment with GM-1111 significantly reduced the development of lesions of the tongue in a dose-dependent manner.

OM Figures

Pulsipher et al. PLoS One 2021

bottom of page